"I'm not persuaded that the LiGHT trial adds a lot of value. The end point was not met and no amount of post-hoc analysis (i.e. removing the non-responders from the data) can maintain the random properties of the original data. This is why the FDA is most unlikely to accept this trial as proof of efficacy. Alas another Phase III trial will be needed, this time with participants selected on the basis of anticipated efficacy (ie disease not too far advanced)."
Are you getting mixed up with the 2RT results?
Light trial was for SLT and that was a positive development for Ellex.
"I'm not persuaded that the LiGHT trial adds a lot of value. The...
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
0.010(4.26%) |
Mkt cap ! $56.11M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 24.5¢ | 23.0¢ | $99.68K | 418.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7787 | 24.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.5¢ | 7832 | 2 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| EYE (ASX) Chart |